{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:55:39Z","timestamp":1780775739773,"version":"3.54.1"},"reference-count":55,"publisher":"SAGE Publications","issue":"2_suppl","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:p>Recent evidence linking hyperprolactinaemia to longer-term clinical sequelae, including osteoporosis, hip fractures and possibly breast cancer, is increasing clinical awareness of the relevance of hyperprolactinaemia. A review of the literature finds clinical trials reporting some degree of comparative prolactin data among antipsychotics. Many of the randomised clinical trials (RCTs) do not report categorical rates of hyperprolactinaemia in contrast with the naturalistic studies, making it complex for clinicians to evaluate the extent and severity of hyperprolactinaemia.<\/jats:p>\n                  <jats:p>Hyperprolactinaemia is one of the commonest adverse events reported in clinical trials and can be found in association with all antipsychotics. The highest rates of hyperprolactinaemia are reported in association with risperidone and amisulpride, often as high as 80\u201490% of all female subjects and consistently greater than with the typical antipsychotics. Significant rates of hyperprolactinaemia of lesser severity and more transience have also been reported in association with other atypical antipsychotics.<\/jats:p>","DOI":"10.1177\/0269881107088435","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T07:38:40Z","timestamp":1210664320000},"page":"46-55","source":"Crossref","is-referenced-by-count":117,"title":["A review of the association between antipsychotic use and hyperprolactinaemia"],"prefix":"10.1177","volume":"22","author":[{"given":"Chris","family":"Bushe","sequence":"first","affiliation":[{"name":"MB BS Eli Lilly and Company Ltd, Basingstoke, UK, beesbeesbees@blueyonder.co.uk,\rbushe_chris@lilly.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shaw","sequence":"additional","affiliation":[{"name":"Elmfield House MHRC, Halifax, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C","family":"Peveler","sequence":"additional","affiliation":[{"name":"University of Southampton, Royal South Hants Hospital,\rSouthampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0704"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107078281"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088436"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.07.003"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107066333"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(97)00036-4"},{"key":"atypb8","volume-title":"British Association of Psychopharmacology 2005 Summer Meeting"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.11.009"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80086-7"},{"key":"atypb11","volume-title":"Equal treatment closing the gap","year":"2006"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00897.x"},{"key":"atypb13","first-page":"551","volume":"246","year":"2000","journal-title":"Clin Chem"},{"key":"atypb14","first-page":"20","volume":"22","year":"2007","journal-title":"J Psychopharmacol"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.023671"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000239791.91330.48"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.1.162"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.10.007"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000186738.84276.9f"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0909"},{"key":"atypb21","first-page":"147","volume":"90","year":"2007","journal-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial Schizophr Res"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0206"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00127-0"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2005.12.006"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00011"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.5.1010"},{"key":"atypb27","first-page":"419","volume":"25","year":"2004","journal-title":"Neuro Endocrinol Lett"},{"key":"atypb28","first-page":"803","volume":"27","year":"2006","journal-title":"Neuro Endocrinol Lett"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31802dda4a"},{"key":"atypb30","doi-asserted-by":"crossref","unstructured":"Lee BH, Kin YK (2006) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients Prog Neuropsychopharmacol Biol Psychiatry 30: 658-662 [Epub 2006 Feb 7]","DOI":"10.1016\/j.pnpbp.2005.11.037"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103174011"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.6.503"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1002\/hup.811"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0614"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1108"},{"key":"atypb37","volume-title":"Technology Appraisal Guidance No. 43. Guidance on the use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia","year":"2002"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000150223.31007.e0"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.07.006"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0910"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.03.027"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.5.947"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.181.1.49"},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00002"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00010"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.1.133"},{"key":"atypb48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1870"},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.01.032"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3369"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.6356"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0109"},{"key":"atypb53","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.12.1147"},{"key":"atypb54","first-page":"270","volume":"91","year":"2007","journal-title":"Prolactin, menstrual irregularities, quality of life Schizophr Res"},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(02)00022-7"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881107088435","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881107088435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:10:41Z","timestamp":1777507841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881107088435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":55,"journal-issue":{"issue":"2_suppl","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1177\/0269881107088435"],"URL":"https:\/\/doi.org\/10.1177\/0269881107088435","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}